Zacks Small Cap Research – MGRM: The De-Risking of the Monogram Story from FDA Clearance and Initiation of Live Patient Trials Supports Price Target of $6.00 – Go Health Pro
By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT Monogram (NASDAQ:MGRM) reported 1st quarter 2025 financial results on May 14, 2025 which were largely in line with our expectations. Research and development expenses for the quarter were $2.26 million compared to $2.41 million in the prior year period. The R&D decrease was primarily … Read more